Whey Protein Micelles and Thermogenesis in Overweight Subjects (Thermowhey)
Whey Protein Micelles and Thermogenesis In Overweight Subjects
The main objective of the trial is to measure the thermogenic effect of two different doses of whey protein microgels.
It will be a randomized crossover double-blind design conducted in 20 subjects.
調査の概要
詳細な説明
Primary objective and outcome:
The primary objective of the trial is to measure the thermogenic effect of two different doses of whey protein microgels (WPM).
Secondary objectives and outcomes:
Explore the mechanism of action of WPM on thermogenesis including:
Protein turnover in response to the dose and the source of protein (WPM versus casein) Insulinemic and glycemic response to the dose and source of protein (WPM versus casein)
Design: The proposed study is a randomized double-blind, placebo-controlled, single center, crossover design.
At the start of the study, subjects will be randomly assigned to 4 different groups in a crossover design, where they will be asked to consume a beverage containing Product 1: 0g of protein (maltodextrin control) Product 2: 30g of WPM Product 3: 50g of WPM Product 4: 50g of micellar casein (MC) Number of subjects: The number of subjects will be 15. Sufficient subjects should be recruited to provide a 30% drop-out rate. Therefore 20 subjects will be needed including drop-outs.
研究の種類
入学 (実際)
段階
- 適用できない
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Overweight (BMI range between 25.0 and 29.9 kg per m2 Healthy Having obtained his/her subjects over 20 year informed consent.
Exclusion Criteria:
Chronic or acute diseases affecting protein metabolism (diabetes, renal insufficiency, CVD, liver disease), dyslipidemia History of varicose or venous stases Recent major surgery (3 months) History of major gastro-intestinal surgery (gastric bypass, intestinal resection etc…) Malabsorption disorders History of cancer within the past year Significant weight loss during the last 3 months Food allergies, especially cow milk protein. Pregnancy or lactation Special diets especially vegetarian, high protein (≥ 1.6 g/kg) or weight loss program Abnormal Food Frequency Questionnaire Aversion to vanilla or chocolate aromas Smoking Moderate to intense physical activity > 2 hours/week Hematocrit <40 for males and < 36 for females Blood donation within 3 months of study start and 3 months after study end Regular consumption of medication and supplements i.e. any treatment affecting thermogenesis or nutrient metabolism in general such as corticosteroids, insulin, androgens, antibiotics and nutritional supplements (multivitamins, protein shakes).
Have a high alcohol consumption (more than 1 drink/day) Consumption of illicit drugs Subject who cannot be expected to comply with the study procedures, including consuming the test products.
Currently participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
プラセボコンパレーター:Control (WPM 0)
400 mL beverage with 85.0% maltodextrine, 15.0% fat and 0% of whey protein micelles Product given once after 1 hour of monitoring for baseline
|
43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
|
アクティブコンパレータ:WPM 30
400 mL beverage with 43.7% of maltodextrine, 15.2 % fat and 41.1% (30 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
|
16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
85.0 % maltodextrin,15.0%
fat, 0% WPM
|
アクティブコンパレータ:WPM 50
400 mL beverage with 16.3% of maltodextrine, 15.2 % fat and 68.5% (50 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
|
43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
85.0 % maltodextrin,15.0%
fat, 0% WPM
|
アクティブコンパレータ:MC 50
400 mL beverage with 16.7% of maltodextrine, 15.0 % fat and 68.2% (50 g) of whey protein micelles 50 g of micellar casein Product given once after 1 hour of monitoring for baseline
|
43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
85.0 % maltodextrin,15.0%
fat, 0% WPM
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
thermic effect of food
時間枠:7 hours from baseline measurements
|
gas exchanges through indirect calorimetry
|
7 hours from baseline measurements
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Whole body protein turnover
時間枠:7 hours from baseline
|
protein synthesis and breakdown
|
7 hours from baseline
|
協力者と研究者
捜査官
- 主任研究者:Maurice Beaumont, MD, PhD、Société des Produits Nestlé (SPN)
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
WPM 30の臨床試験
-
Alain KaelinUniversity of Applied Sciences and Arts of Southern Switzerland; Clinical Trial Unit Ente Ospedaliero...募集
-
National Yang Ming University完了
-
Rush University Medical Center募集
-
University Malaysia SarawakUniversity of Malaya完了